Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Medicamento en fase II de la prueba de concepto para el tratamiento de la enfermedad de Huntington

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190307001
Publicado:
08/03/2019
Caducidad:
08/03/2020
Resumen:
Una empresa barcelonesa especializada en descubrimiento y desarrollo de fármacos en fase clínica ofrece un medicamento reposicionado para el tratamiento de los movimientos de la corea asociados a la enfermedad de Huntington. También puede emplearse para trastornos del movimiento hipercinéticos asociados al síndrome de Tourette, discinesia tardía y hemibalismo. Se trata de una pequeña molécula que actualmente se encuentra en la fase II de la prueba de concepto. En comparación con los tratamientos disponibles en el mercado para tratar la enfermedad, este medicamento es seguro y también puede utilizarse en pacientes con Huntington que padecen afecciones neurológicas, como depresión, psicosis y comportamiento agresivo. La empresa busca compañías farmacéuticas y biotecnológicas con el fin de establecer acuerdos de licencia.

Details

Tittle:
A Phase 2a-stage drug for Huntington´s disease for license agreement
Summary:
A clinical-stage drug discovery and development company based in Barcelona, Spain, is offering a repurposed drug for the treatment of chorea movements associated with Huntington´s disease. It is a small molecule that is currently undergoing Phase 2a proof-of-concept. The company is looking for license agreements.
Description:
The Spanish company has developed an efficient and predictive artificial intelligence (AI) technology for drug reprofiling.
Through its AI technology, the company has built its own pipeline of assets in the Central Nervous System (CNS) orphan disease space—the company´s therapeutic focus.
The company´s pipeline consists of clinical-stage assets for Huntington´s disease and Adrenoleukodystrophy, as well as preclinical-stage assets for Adrenomyeloneuropathy, Phenylketonuria and Niemann-Pick disease.
The current most advanced asset is for Huntington´s disease which is in Phase 2a, with preliminary clinical data expected in September 2019.
The technology is a VMAT-2 inhibitor being developed as a prevention and treatment of chorea movements associated with Huntington´s disease. It may also be used for hyperkinetic movement disorders associated with Tourette´s syndrome, tardive dyskinesia and hemiballism.
The company´s business model involves drug discovery, preclinical/clinical development and out-licensing after Phase 2a proof-of-concept. The company is seeking pharmaceutical and biotechnology companies for a license agreement and is flexible with reference to deal structure, depending on the prospective licensee.
Advantages and Innovations:
The technology is a repurposed drug with an already established safety profile for its primary indication. Compared to the available treatments for Huntington´s disease on the market, which have black box warning, it is safe and may also be used in Huntington´s disease patients with neurological afflictions such as depression, psychosis and aggressive behaviour.
The AI platform has demonstrated success through the company´s first asset for Transthyretin Amyloidosis which reached Phase 2a completion in five years since its discovery in 2011 and was licensed for worldwide rights to a US-based pharmaceutical company. Recently, the technology has yet again proven its predictive accuracy through the Phase 2a milestone achieved by the company´s second asset for Huntington´s disease in the 3rd quarter of 2018.
Stage of Development:
Concept stage
IPs:
Patent(s) applied for but not yet granted,Patents granted
CommeR Statunts Regarding IPR Status:
WW New Use Patents

Partner sought

Type and Role of Partner Sought:
The company seeks to collaborate with biotechnology and/or pharmaceutical companies that wish to expand their pipeline through licensing the company´s clinical- or preclinical-stage assets.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
01003003 Artificial Intelligence (AI)
06001002 Investigaciones clínicas, ensayos
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos
05001002 Química computacional y modelado